Market revenue in 2023 | USD 3.6 million |
Market revenue in 2030 | USD 4.8 million |
Growth rate | 4.2% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 36.11% in 2023. Horizon Databook has segmented the UAE cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
Due to the increasing prevalence of various chronic diseases, a supportive regulatory framework, the entry of new competitors, and the growing annual investments of foreign pharmaceutical companies, the market for cell and gene therapy bioanalytical testing services is anticipated to grow steadily in the UAE.
Moreover, domestic manufacturers are driving the market by using a variety of strategies to increase their pharmaceutical manufacturing capacities and geographic presence. These factors are projected to boost pharmaceutical manufacturing in the country.
Furthermore, the UAE is witnessing an increase in the prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders, just like many other countries. Cell and gene therapies provide promising possibilities for treating certain disorders.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into UAE cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account